AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Principia Biopharma Inc., a private, clinical-stage biopharmaceutical company, announced today that they have entered a collaboration for the development of oral immunoproteasome inhibitors. The collaboration is aimed at developing first-in-class oral therapies that bring the power of proteasome inhibition safely into the field of immunology.
"Principia has discovered a novel technology that has the potential to enhance the treatment landscape for a variety of immunological diseases," said Lisa Olson, vice president, immunology research, AbbVie. "The combination of AbbVie's world-class expertise in immunology drug development with Principia's innovative approach to immunoproteasome inhibitors may offer patients a new class of therapies to treat serious and chronic conditions."
"As a world leader in immunology and inflammation, AbbVie is an ideal fit for Principia's reversible covalent inhibitors, also known as Tailored Covalency™," said Martin Babler, chief executive officer, Principia. "This collaboration brings together the best of both companies, accelerating our program toward the clinic."